Antiphospholipid antibodies and the antiphospholipid syndrome I: Pathogenesis, clinical features, diagnosis, and management

Seminars in Thrombosis and Hemostasis

Volumn 34, Issue 3, 2008, Pages 213-218

  Wong, Richard C W ^a   Favaloro, Emmanuel J ^b  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ACETYLSALICYLIC ACID; ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; CORTICOSTEROID; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBRINOGEN RECEPTOR ANTAGONIST; GLYCOPROTEIN IIB; HEPARIN; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERCELLULAR ADHESION MOLECULE 1; LIPOCORTIN 5; LOW MOLECULAR WEIGHT HEPARIN; LUPUS ANTICOAGULANT; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHOLIPID ANTIBODY; PROTEIN S; SERINE PROTEINASE; THROMBOPLASTIN; TOLL LIKE RECEPTOR; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR; WARFARIN;

ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; CHICKENPOX; CLINICAL FEATURE; COMPLEMENT ACTIVATION; DISEASE ASSOCIATION; DRUG SAFETY; EDITORIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL MOUSE; FETUS BLOOD; FETUS WASTAGE; HEPARIN INDUCED THROMBOCYTOPENIA; HOSPITAL ADMISSION; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY DISEASE; KNOWLEDGE DISCOVERY; LIVEDO RETICULARIS; MIXED INFECTION; NEUROLOGIC DISEASE; NONHODGKIN LYMPHOMA; PATHOGENESIS; PLASMAPHERESIS; PREGNANCY; PRIORITY JOURNAL; PROTEIN S DEFICIENCY; RADIOIMMUNOASSAY; RETROSPECTIVE STUDY; RISK REDUCTION; SENSITIVITY AND SPECIFICITY; SJOEGREN SYNDROME; STREPTOCOCCUS INFECTION; STROKE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; THROMBOSIS; THROMBOSIS PREVENTION; TRANSIENT ISCHEMIC ATTACK; TROPHOBLAST;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; HUMANS;

EID: 50249093784     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0028-1082264     Document Type: Editorial

References (8)

1. Harris EN, Gharavi AE, Boey ML, et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983;2:1211-1214
2. Wilson WA. Classification criteria for antiphospholipid syndrome. Rheum Dis Clin North Am 2001;27:499-505
3. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306
4. Favaloro EJ, Wong RC. Antiphospholipid antibodies and the antiphospholipid syndrome II: limitations, standardization, and clinical utility of laboratory testing. Semin Thromb Hemost 2008;34: (in press)
5. Erkan D, Harrison MJ, Levy R, et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum 2007;56:2382-2391
6. Janardhan V, Wolf PA, Kase CS, et al. Anticardiolipin antibodics and risk of ischemic stroke and transient ischemic attack: the Framingham cohort and offspring study. Stroke 2004;35:736-741
7. Muñoz-Rodriguez FJ, Font J, Cervera R, et al. Clinical study and follow-up of 100 patients with the antiphospholipid syndrome. Semin Arthritis Rheum 1999;29:182-190
8. Asherson RA. The catastrophic antiphospholipid syndrome. J Rheumatol 1992;19:508-512